1,2-dihydro-1-carbethoxy-2-(2-naphthylmethyl)-3H-indazol-3-one | 120275-83-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1,2-dihydro-1-carbethoxy-2-(2-naphthylmethyl)-3H-indazol-3-one
• 英文别名: 1,2-dihydro-1-carboethoxy-2-(2-naphthylmethyl)-3H-indazol-3-one；Ethyl 2-(naphthalen-2-ylmethyl)-3-oxoindazole-1-carboxylate
• CAS: 120275-83-4
• 化学式: C₂₁H₁₈N₂O₃
• 分子量: 346.386
• InChiKey: ZXEIPKJXQARUPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  49.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1,2-dihydro-1-carbethoxy-2-(2-naphthylmethyl)-3H-indazol-3-one 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 0.25h， 以85%的产率得到1,2-dihydro-2-(2-naphthylmethyl)-3H-indazol-3-one
  参考文献：
  名称：

  Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity

  摘要：

  Since the hypothetical mechanisms of hydroperoxydation of arachidonic acid by, respectively, 5-lipoxygenase (5-LPO) and cyclooxygenase (CO) involve a redox cycle, a compound which reduces 5-LPO and CO to their inactive state would give a nonselective inhibitor of both enzymes. Structural modifications of such a compound could be expected to give improved potency and selectivity for 5-LPO and oral activity. Such an approach has led to the discovery of 1,2-dihydroindazol-3-ones which are potent 5-LPO inhibitors with various degrees of selectivity. Structure-activity relationship studies indicated that while N-1,N-2-unsubstituted and N-1-substituted derivatives are orally inactive, N-2-alkyl derivatives are orally active and inhibit both 5-LPO and CO. In contrast, N-2-benzyl derivatives are selective for 5-LPO but possess only weak oral activity. Further structural modifications have identified ICI 207968 [1,2-dihydro-2-(3-pyridylmethyl)-3H-indazol-3-one, 21a] which combines potent oral activity and high selectivity. Methemoglobin (MHb) induction by 21a in dog blood precluded its development for clinical use. Attempts at dissociating 5-LPO inhibitory properties and MHb formation showed that MHb formation in vitro seemed to be related to the redox potential of the compounds whereas 5-LPO inhibition was not. This study led to a series of 4-(N-n-pentylcarbamoyl)indazolinones which maintained in vitro 5-LPO potency but did not induce MHb.

  DOI：

  10.1021/jm00107a023
• 作为产物：
  描述：

  2-溴甲基萘 以64%的产率得到1,2-dihydro-1-carbethoxy-2-(2-naphthylmethyl)-3H-indazol-3-one
  参考文献：
  名称：

  Therapeutic preparations containing indazole derivatives

  摘要：

  该发明涉及含有式I的1,2-二氢-3H-吲唑-3-酮衍生物的药物组合物 其中Ra为氢，卤素，硝基，羟基，（2-6C）烷酰氧基，（1-6C）烷基，（1-6C）烷氧基，氟代（1-4C）烷基，（2-6C）烷酰基，氨基，（1-6C）烷基氨基，二-[(1-4C）烷基]氨基，（2-6C）烷酰氨基或羟基（1-6C）烷基；Rb为氢，卤素，（1-6C）烷基或（1-6C）烷氧基；Y为式--A.sup.1 --X--A.sup.2 --Q的基团，其中A.sup.1为（1-6C）烷基，（3-6C）烯基，（3-6C）炔基或环（3-6C）烷基，或A.sup.1为苯基；X为氧，硫，亚硫基，砜基，亚砜基，亚胺基，（1-6C）烷基亚胺基，（1-6C）烷酰亚胺基，亚氨基甲酰基或苯基，或X为与A.sup.2的直接连接；A.sup.2为（1-6C）烷基，（3-6C）烯基或（3-6C）炔基，或A.sup.2为环（3-6C）烷基或与Q的直接连接，或基团--A.sup.1 --X--A.sup.2 --为与Q的直接连接；或Y为（2-10）烷基，（3-10C）烯基或（3-6C）炔基；Q为芳基或杂芳基。该发明还提供了新型1,2-二氢-3H-吲唑-3-酮，其生产工艺以及用于制备治疗各种过敏和炎症性疾病药物的1,2-二氢-3H-吲唑-3-酮的用途。

  公开号：

  US05173496A1

文献信息

• BRUNEAU, P.;DELVARE, C.;EDWARDS, M. P.;MCMILLAN, R. M., J. MED. CHEM. , 34,(1991) N, C. 1028-1036
  作者：BRUNEAU, P.、DELVARE, C.、EDWARDS, M. P.、MCMILLAN, R. M.

  DOI：——

  日期：——
• Therapeutic preparations
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0284174B1

  公开（公告）日：1992-07-29
• US5173496A
  申请人：——

  公开号：US5173496A

  公开（公告）日：1992-12-22
• Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity
  作者：P. Bruneau、C. Delvare、M. P. Edwards、R. M. McMillan

  DOI：10.1021/jm00107a023

  日期：1991.3

  Since the hypothetical mechanisms of hydroperoxydation of arachidonic acid by, respectively, 5-lipoxygenase (5-LPO) and cyclooxygenase (CO) involve a redox cycle, a compound which reduces 5-LPO and CO to their inactive state would give a nonselective inhibitor of both enzymes. Structural modifications of such a compound could be expected to give improved potency and selectivity for 5-LPO and oral activity. Such an approach has led to the discovery of 1,2-dihydroindazol-3-ones which are potent 5-LPO inhibitors with various degrees of selectivity. Structure-activity relationship studies indicated that while N-1,N-2-unsubstituted and N-1-substituted derivatives are orally inactive, N-2-alkyl derivatives are orally active and inhibit both 5-LPO and CO. In contrast, N-2-benzyl derivatives are selective for 5-LPO but possess only weak oral activity. Further structural modifications have identified ICI 207968 [1,2-dihydro-2-(3-pyridylmethyl)-3H-indazol-3-one, 21a] which combines potent oral activity and high selectivity. Methemoglobin (MHb) induction by 21a in dog blood precluded its development for clinical use. Attempts at dissociating 5-LPO inhibitory properties and MHb formation showed that MHb formation in vitro seemed to be related to the redox potential of the compounds whereas 5-LPO inhibition was not. This study led to a series of 4-(N-n-pentylcarbamoyl)indazolinones which maintained in vitro 5-LPO potency but did not induce MHb.
• Therapeutic preparations containing indazole derivatives
  申请人：ICI Pharma

  公开号：US05173496A1

  公开（公告）日：1992-12-22

  The invention concerns pharmaceutical compositions containing a 1,2-dihydro-3H-indazol-3-one derivative of the formula I ##STR1## wherein Ra is hydrogen, halogeno, nitro, hydroxy, (2-6C)alkanoyloxy, (1-6C)alkyl, (1-6C)alkoxy, fluoro-(1-4C)alkyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-4C)alkyl]amino, (2-6C)alkanoylamino or hydroxy-(1-6C)alkyl; Rb is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy; and Y is a group of the formula --A.sup.1 --X--A.sup.2 --Q in which A.sup.1 is (1-6C)alkylene, (3-6C)alkenylene, (3-6C)alkynylene or cyclo(3-6C)alkylene, or A.sup.1 is phenylene; X is oxy, thio, sulphinyl, sulphonyl, imino, (1-6C)alkylimino, (1-6C)alkanoylimino, iminocarbonyl or phenylene, or X is a direct link to A.sup.2 ; A.sup.2 is (1-6C)alkylene, (3-6C)alkenylene or (3-6C)alkynylene or A.sup.2 is cyclo(3-6C)alkylene or is a direct link to Q, or the group --A.sup.1 --X--A.sup.2 -- is a direct link to Q; or Y is (2-10)alkyl, (3-10C)alkenyl or (3-6C)alkynyl; and Q is aryl or heteroaryl. The invention also provides novel 1,2-dihydro-3H-indazol-3-ones, processes for their production and the use of 1,2-dihydro-3H-indazol-3-ones for the manufacture of medicaments for the treatment of various allergic and inflammatory diseases.

  该发明涉及含有式I的1,2-二氢-3H-吲唑-3-酮衍生物的药物组合物 其中Ra为氢，卤素，硝基，羟基，（2-6C）烷酰氧基，（1-6C）烷基，（1-6C）烷氧基，氟代（1-4C）烷基，（2-6C）烷酰基，氨基，（1-6C）烷基氨基，二-[(1-4C）烷基]氨基，（2-6C）烷酰氨基或羟基（1-6C）烷基；Rb为氢，卤素，（1-6C）烷基或（1-6C）烷氧基；Y为式--A.sup.1 --X--A.sup.2 --Q的基团，其中A.sup.1为（1-6C）烷基，（3-6C）烯基，（3-6C）炔基或环（3-6C）烷基，或A.sup.1为苯基；X为氧，硫，亚硫基，砜基，亚砜基，亚胺基，（1-6C）烷基亚胺基，（1-6C）烷酰亚胺基，亚氨基甲酰基或苯基，或X为与A.sup.2的直接连接；A.sup.2为（1-6C）烷基，（3-6C）烯基或（3-6C）炔基，或A.sup.2为环（3-6C）烷基或与Q的直接连接，或基团--A.sup.1 --X--A.sup.2 --为与Q的直接连接；或Y为（2-10）烷基，（3-10C）烯基或（3-6C）炔基；Q为芳基或杂芳基。该发明还提供了新型1,2-二氢-3H-吲唑-3-酮，其生产工艺以及用于制备治疗各种过敏和炎症性疾病药物的1,2-二氢-3H-吲唑-3-酮的用途。